Metastatic Breast Cancer in Gastrointestinal Systems

Metastatic breast cancer to the gastrointestinal (GI) tract represents an uncommon but clinically significant pattern of dissemination, most frequently observed in invasive lobular carcinoma. Lesions can involve the stomach, small intestine, colon and, less commonly, the oesophagus. Patients often present with nonspecific symptoms such as abdominal pain, altered bowel habits, bleeding or weight loss, which can delay diagnosis. Imaging modalities, including contrast-enhanced computed tomography and positron emission tomography, alongside endoscopic evaluation and biopsy, are essential to distinguish metastatic deposits from primary GI malignancies. Molecular studies have revealed distinct mutational profiles and microenvironmental interactions in GI metastases compared with other distant sites, underscoring the need for tailored therapeutic strategies. Systemic treatment typically comprises endocrine therapy for hormone-receptor-positive disease, often combined with targeted agents, while local endoscopic or surgical interventions may palliate obstructive symptoms. Improved recognition of atypical metastatic patterns and advances in diagnostic biomarkers are refining patient management and prognostication.

Research from Nature Portfolio

Recent studies have employed comprehensive genomic profiling of GI metastases, demonstrating enrichment of ESR1 mutations and alterations in PI3K-AKT signalling that may confer resistance to standard endocrine regimens. Single-cell transcriptomic analyses of gastric metastatic lesions have identified tumour-associated fibroblast subsets that secrete chemokines promoting invasive behaviour, suggesting novel stromal targets. Spatial proteomics investigations in colorectal metastases have delineated distinct immune-suppressive niches driven by interactions between disseminated cancer cells and local microbiota, pointing to potential benefits of combining immunotherapy with microbiome modulation. Finally, liquid-biopsy platforms utilising circulating tumour DNA have shown promise in detecting occult GI involvement earlier than conventional imaging, enabling more timely treatment adjustments.

Metastatic Breast Cancer in Gastrointestinal Systems publication trend

The graph below shows the total number of articles in metastatic breast cancer in gastrointestinal systems across all publications each year (not limited to Nature Index journals).

Technical terms

Invasive lobular carcinoma (ILC): A subtype of breast cancer characterised by discohesive tumour cells that frequently metastasise to the gastrointestinal tract.

Endocrine therapy: Systemic treatment targeting oestrogen receptor pathways, commonly employing aromatase inhibitors or selective receptor modulators.

Immunohistochemistry: Laboratory technique using specific antibodies to visualise protein expression in tissue biopsies for diagnostic confirmation.

Circulating tumour DNA (ctDNA): Fragments of DNA released into the bloodstream by cancer cells, serving as a non-invasive biomarker of tumour burden and metastatic spread.

References

1. Widespread Metastasis to the Stomach 10 Years After Primary Breast Cancer. Medicine (2020).